November #159 : Just the Facts, Ma’am - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Who Wants to Be an AIDS Advocate?

Let’s Get Ready to Rally!

When Pigs Fly

Just the Facts, Ma’am

Breath of Life?

Staying Alive

Medicine Chest

Need a Doctor? Call a Nurse.


Dollar Days

Booty Boost

Take Home Testing

Inglourious Adsters?

Show Us the Money

Acting Up

The Defense Rests

Healthy Debate

Editor's Letter-November 2009

The Power of 'U'

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

Scroll down to comment on this story.

email print

November 2009

Just the Facts, Ma’am

by Laura Whitehorn

At long last, women get some answers on whether HIV affects them differently than men.

In women, HIV progresses more rapidly

It’s a long-standing mystery: Why do women with untreated HIV progress faster to AIDS than men with similar viral loads? A research team at the Ragon Institute of MGH, MIT and Harvard has uncovered a clue. It seems that a family of white blood cells (dendritic cells) in pre-menopausal women produces more of a protein that causes CD4 cells to go haywire, ultimately speeding up damage to the immune system.

Dendritic cells (DCs) detect germs in the body. They secrete alpha interferon, which stimulates other immune cells. Sometimes, as with HIV and some other chronic infections, the DCs overstimulate the immune cells. Harvard’s Marcus Altfeld, MD, one of the researchers, says that female hormones (in this study, progesterone) may spark DCs to produce more interferon in women compared with men.

It’s unclear whether the results apply to people taking HIV meds. Because people with undetectable viral loads still harbor HIV, Altfeld told POZ, treatment might not eradicate the sex-linked difference. “We plan to explore that,” he adds.

How will this help women—and maybe men—resist HIV immune damage? “We [could develop] drugs to disconnect HIV from immune activation,” Altfeld says, “so the virus would replicate without producing pathology.” If that sounds fantastic, Altfeld offers this backup: “Sooty Mangabey monkeys have viral replication [of a simian version of HIV] without immune activation—and they don’t get AIDS.”

Moreover, the same overactive immune response seems to be responsible for women’s higher incidence of autoimmune diseases such as lupus. “Companies are developing drugs for lupus [to disrupt this immune overstimulation process],” Altfeld says. “We’ll know in a year or two whether such drugs work and are safe for lupus; then we might test them to block HIV-induced immune activation.”

Lack of  housing undermines care and treatment

“Housing equals health care for people living with HIV/AIDS. Even the threat of homelessness can lead to unnecessary illness and premature death. Permanent housing means access to medication and the ability to reenter the labor force. [Yet] among HIV-positive women of all races, 48 percent rely on subsidized housing, are living in transitional [housing] or are marginally housed. One percent reported living on the street or [being] homeless.”

Source: HIV-Positive Voices in America, April 2009

Some HIV meds work as well in women as in men

An HIV combo that included Norvir (ritonavir)–boosted Prezista (darunavir) worked similarly in women as in men in the GRACE study (Gender, Race and Clinical Experience).

From the epidemic’s beginnings, most HIV drug studies have been performed in men—predominantly white men. GRACE, which ran from 2006 to 2008,  was designed to fill in some of the blanks in HIV treatment information for women, especially black and Latina women. Sixty-seven percent of GRACE participants were women, and only about a quarter of all participants were white.

Some gender and sex differences did emerge. For instance, more women than men dropped out during the year covered by the study report, and women reported more side effects (only some of which resulted from Prezista/Norvir).


Search: HIV, women, care, treatment, medicine, CD4, immune system, pre-menopausal

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.